Ragosa Mark 4

What Happened
Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals (KNSA), had 2,694 restricted share units (RSUs) convert to Class A ordinary shares on April 7, 2026. As part of the vesting/settlement, 1,303 shares were surrendered to cover tax withholding at $48.94 per share for a cash value of about $63,769, leaving a net 1,391 shares delivered to Ragosa. The filing shows the conversion of RSUs (derivative conversion) and the related withholding; this is a routine vesting/tax-withholding event, not an open-market sale.

Key Details

• Transaction date: 2026-04-07; Form 4 filed 2026-04-08 (timely, within typical Form 4 window).
• Conversion: 2,694 RSUs converted to 2,694 shares (transaction code M).
• Tax withholding: 1,303 shares withheld/disposed to cover taxes at $48.94/share for ~$63,769 (transaction code F).
• Net shares received (based on entries): 2,694 − 1,303 = 1,391 shares.
• Footnotes: F1 — each RSU converts to one Class A share; F2 — RSUs vest 25% per year from April 7, 2022 (four-year schedule).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• This was not an open-market sale; shares were surrendered to satisfy tax obligations on vested RSUs.

Context

• This was a scheduled RSU vesting and settlement (not an exercised market option or discretionary sale). Converting RSUs and withholding shares for taxes is a common, routine corporate compensation action and does not necessarily indicate a change in insider sentiment.
• For clarity: transaction code M indicates conversion/exercise of a derivative (here RSUs converting to shares); code F indicates shares withheld or surrendered to satisfy tax or exercise-price obligations.